Gastrointestinal Stromal Tumors (GIST)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia
Protocol 01-2017: RFA for Anal Intraepithelial Neoplasia A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using The BARRX™ Anorectal Wand (Clinical Protocol 01-2017) AUGUST 31, 2017 Page 1 of 40 Protocol 01-2017: RFA for Anal Intraepithelial Neoplasia PROTOCOL SIGNATURE PAGE I, , Principal Investigator at site , agree to conduct and follow this protocol: PROTOCOL 01-2017: A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for Anal Intraepithelial Neoplasia using the Barrx™ Anorectal Wand as written according to FDA guidelines. I understand that no deviations from the above protocol may be made without written permission from the Protocol Chair(s). _________________________________ _____________________ Signature Date (mm/dd/yyyy) Page 2 of 40 Protocol 01-2017: RFA for Anal Intraepithelial Neoplasia P ROT O COL S U M M ARY Title A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for Anal Intraepithelial Neoplasia using the Barrx™ Anorectal Wand Design Multi-center prospective trial involving up to 70 subjects Subject Population HIV-positive and HIV-negative subjects with intra-anal intraepithelial neoplasia (AIN) containing at least one high- grade squamous intraepithelial lesions (HSIL) involving the squamocolumnar junction (SCJ). Objective Assess the safety, and efficacy of circumferential radiofrequency ablation (RFA) to the anal canal using the FDA cleared Barrx™ Anorectal Wand to eradicate anal -
Detail Report
Supplemental Update Report CR Number: 2012319113 Implementation Date: 16-Jan-19 Related CR: 2012319113 MedDRA Change Requested Add a new SMQ Final Disposition Final Placement Code # Proposed SMQ Infusion related reactions Rejected After Suspension MSSO The proposal to add a new SMQ Infusion related reactions is not approved after suspension. The ICH Advisory Panel did approve this SMQ topic to go into the development phase and it Comment: underwent testing in three databases (two regulatory authorities and one company). However, there were numerous challenges encountered in testing and the consensus decision of the CIOMS SMQ Implementation Working Group was that the topic could not be developed to go into production as an SMQ. Most notably, in contrast to other SMQs, this query could not be tested using negative control compounds because it was not possible to identify suitable compounds administered via infusion that were not associated with some type of reaction. In addition, there is no internationally agreed definition of an infusion related reaction and the range of potential reactions associated with the large variety of compounds given by infusion is very broad and heterogenous. Testing was conducted on a set of around 500 terms, the majority of which was already included in Anaphylactic reaction (SMQ), Angioedema (SMQ), and Hypersensitivity (SMQ). It proved difficult to identify potential cases of infusion related reactions in post-marketing databases where the temporal relationship of the event to the infusion is typically not available. In clinical trial databases where this information is more easily available, users are encouraged to provide more specificity about the event, e.g., by reporting “Anaphylactic reaction” when it is known that this event is temporally associated with the infusion. -
Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors
Journal of Nuclear Medicine, published on May 11, 2012 as doi:10.2967/jnumed.111.098699 Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors Masahiro Yanagawa*1, Mitsuaki Tatsumi*1,2, Hiroshi Miyata3, Eiichi Morii4, Noriyuki Tomiyama1, Tadashi Watabe2, Kayako Isohashi2, Hiroki Kato2, Eku Shimosegawa2, Makoto Yamasaki3, Masaki Mori3, Yuichiro Doki3, and Jun Hatazawa2 1Department of Radiology, Osaka University Graduate School of Medicine, Suita-city, Osaka, Japan; 2Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita-city, Osaka, Japan; 3Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita-city, Osaka, Japan; and 4Department of Pathology, Osaka University Graduate School of Medicine, Suita-city, Osaka, Japan onstrate the correlation between therapeutic responses and Recently, PET response criteria in solid tumors (PERCIST) have prognosis in patients with esophageal cancer receiving neoadju- been proposed as a new standardized method to assess vant chemotherapy. However, PERCIST was found to be the chemotherapeutic response metabolically and quantitatively. strongest independent predictor of outcomes. Given the signifi- The aim of this study was to evaluate therapeutic response to cance of noninvasive radiologic imaging in formulating clinical neoadjuvant chemotherapy for locally advanced esophageal treatment strategies, PERCIST might be considered more suit- cancer, comparing PERCIST with the currently widely used able for evaluation of chemotherapeutic response to esophageal response evaluation criteria in solid tumors (RECIST). Methods: cancer than RECIST. Fifty-one patients with locally advanced esophageal cancer who Key Words: RECIST; PERCIST; 18F-FDG PET; esophageal cancer; received neoadjuvant chemotherapy (5-fluorouracil, adriamycin, response to therapy and cisplatin), followed by surgery were studied. -
Immunohistochemical Detection of WT1 Protein in a Variety of Cancer Cells
Modern Pathology (2006) 19, 804–814 & 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Immunohistochemical detection of WT1 protein in a variety of cancer cells Shin-ichi Nakatsuka1, Yusuke Oji2, Tetsuya Horiuchi3, Takayoshi Kanda4, Michio Kitagawa5, Tamotsu Takeuchi6, Kiyoshi Kawano7, Yuko Kuwae8, Akira Yamauchi9, Meinoshin Okumura10, Yayoi Kitamura2, Yoshihiro Oka11, Ichiro Kawase11, Haruo Sugiyama12 and Katsuyuki Aozasa13 1Department of Clinical Laboratory, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan; 2Department of Biomedical Informatics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; 3Department of Surgery, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan; 4Department of Gynecology, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan; 5Department of Urology, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan; 6Department of Pathology, Kochi Medical School, Kohasu, Oko-cho, Nankoku City, Kochi, Japan; 7Department of Pathology, Osaka Rosai Hospital, Sakai, Osaka, Japan; 8Department of Pathology, Osaka Medical Center and Research Institute of Maternal and Child Health, Izumi, Osaka, Japan; 9Department of Cell Regulation, Faculty of Medicine, Kagawa University, Miki-cho, Kida-gun, Kagawa, Japan; 10Department of Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; 11Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; 12Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan and 13Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan WT1 was first identified as a tumor suppressor involved in the development of Wilms’ tumor. Recently, oncogenic properties of WT1 have been demonstrated in various hematological malignancies and solid tumors. -
Prognostic Factors Affecting Mortality in Patients with Esophageal Gists
JBUON 2020; 25(1): 497-507 ISSN: 1107-0625, online ISSN: 2241-6293 • www.jbuon.com Email: [email protected] ORIGINAL ARTICLE Prognostic factors affecting mortality in patients with esophageal GISTs Dimitrios Schizas1, George Bagias2, Prodromos Kanavidis1, Demetrios Moris1, Eleftherios Spartalis3, Christos Damaskos3, Nikolaos Garmpis3, Ioannis Karavokyros1, Evangelos P. Misiakos4, Theodore Liakakos1 11st Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece; 2Clinic for General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany; 32nd Department of Propedeutic Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece; 43rd Department of Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. Summary Purpose: Esophageal gastrointestinal stromal tumors (54.3%), followed by tumor enucleation (45.7%). The median (GISTs) compose a very rare clinical entity, representing follow-up period was 34 months; tumor recurrence occurred 0.7% of all GISTs. Therefore, the clinicopathological factors in 18 cases (18.9%) and 19 died of disease (19.2%). The over- that affect mortality are currently not adequately examined. all survival rate was 75.8%. We found out that tumor size We reviewed individual cases of esophageal GISTs found in and high mitotic rate (>10 mitosis per hpf) were significant the literature in order to identify the prognostic factors af- prognostic factors for survival. Presence of symptoms, ul- fecting mortality. ceration, and tumor necrosis as well as tumor recurrence were also significant prognostic factors (p<0.01). Methods: MEDLINE, EMBASE, and the Cochrane Library were systematically searched to identify clinical studies and Conclusions: Esophageal GISTs’ tumor size and mitotic case reports referring to esophageal GISTs. -
Infectious Gastroenteritis Generalised Anxiety Disorder HIV Smoking Associated Cancers
BEST PRACTICE 25 DECEMBER 2009 Infectious gastroenteritis Generalised anxiety disorder HIV bpac nz Smoking associated cancers better medicin e Editorial Team Tony Fraser Professor Murray Tilyard We would like to acknowledge the following people for Clinical Advisory Group their guidance and expertise in developing this edition: Michele Cray Dr Shaun Costello, Dunedin Serena Curtis-Lemuelu Dr Edward Coughlan, Christchurch Dr Rosemary Ikram Professor Tony Dowell, Wellington Dr Cam Kyle Dr Rosemary Ikram, Christchurch Dr Chris Leathart Mr William Pearce, Christchurch Dr Lynn McBain Dr Alan Pithie, Christchurch Adam McRae Dr Gabrielle Ruben, Wellington Janet Maloney-Moni Assoc. Professor Mark Thomas, Auckland Dr Peter Moodie Dr Robyn Toomath, Wellington Associate Professor Jim Reid Dr Neil Whittaker, GP Reviewer, Nelson Associate Professor David Reith Assoc. Professor Michael Williams, Dunedin Professor Murray Tilyard Programme Development Team Rachael Clarke Peter Ellison Best Practice Journal (BPJ) Rebecca Harris Julie Knight ISSN 1177-5645 Noni Richards BPJ, Issue 25, December 2009 Dr Tom Swire Dr AnneMarie Tangney nz Dr Sharyn Willis BPJ is published and owned by bpac Ltd Dave Woods Level 8, 10 George Street, Dunedin, New Zealand. Report Development Team Bpacnz Ltd is an independent organisation that promotes health Justine Broadley care interventions which meet patients’ needs and are evidence Todd Gillies based, cost effective and suitable for the New Zealand context. Lana Johnson We develop and distribute evidence based resources which describe, facilitate and help overcome the barriers to best Web practice. Gordon Smith Bpacnz Ltd is currently funded through contracts with PHARMAC Design and DHBNZ. Michael Crawford Bpacnz Ltd has five shareholders: Procare Health, South Link Management and Administration Health, IPAC, the University of Otago and Pegasus Health. -
The Diagnostic and Prognostic Value of a Liquid Biopsy for Esophageal Cancer: a Systematic Review and Meta-Analysis
cancers Review The Diagnostic and Prognostic Value of a Liquid Biopsy for Esophageal Cancer: A Systematic Review and Meta-Analysis Daisuke Matsushita 1,* , Takaaki Arigami 2 , Keishi Okubo 1, Ken Sasaki 1, Masahiro Noda 1, Yoshiaki Kita 1, Shinichiro Mori 1, Yoshikazu Uenosono 3, Takao Ohtsuka 1 and Shoji Natsugoe 4 1 Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan; [email protected] (K.O.); [email protected] (K.S.); [email protected] (M.N.); [email protected] (Y.K.); [email protected] (S.M.); [email protected] (T.O.) 2 Department of Onco-biological Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan; [email protected] 3 Department of Surgery, Jiaikai Imamura General Hospital, Kagoshima 890-0064, Japan; [email protected] 4 Department of Surgery, Gyokushoukai Kajiki Onsen Hospital, Aira 899-5241, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-99-275-5361; Fax: +81-99-265-7426 Received: 9 September 2020; Accepted: 18 October 2020; Published: 21 October 2020 Simple Summary: The “liquid biopsy” is a novel concept for detecting circulating biomarkers in the peripheral blood of patients with various cancers, including esophageal cancer. There are two main methods to identify circulating cancer related biomarkers such as morphological techniques or molecular biological techniques. -
Pathology of Anal Cancer
Pathology of Anal Cancer a b Paulo M. Hoff, MD, PhD , Renata Coudry, MD, PhD , a, Camila Motta Venchiarutti Moniz, MD * KEYWORDS Anal cancer Anal squamous intraepithelial neoplasia Squamous cell carcinoma Human papilloma virus (HPV) Molecular KEY POINTS Anal cancer is an uncommon tumor, squamous cell carcinoma (SCC) being the most frequent histology corresponding to 80% of all cases. Human papilloma virus (HPV) infection plays a key role in anal cancer development, en- coding at least three oncoproteins with stimulatory properties. SCC expresses CK5/6, CK 13/19, and p63. P16 is a surrogate marker for the presence of HPV genome in tumor cells. INTRODUCTION Anal cancer accounts for approximately 2.4% of gastrointestinal malignancies.1 Although anal cancer is a rare tumor, its frequency is increasing, especially in high- risk groups.2 Tumors in this location are generally classified as anal canal or anal margin. Squamous cell carcinoma (SCC) is the predominant type of tumor and shares many features with cervical cancer. Oncogenic human papilloma virus (HPV) infection plays a major role in both tumors.3 HIV infection is associated with a higher frequency of HPV-associated premalignant lesions and invasive tumors.4 Normal Anatomy of the Anus The anal canal is the terminal part of the large intestine and is slightly longer in male than in female patients. It measures approximately 4 cm and extends from the rectal ampulla (pelvic floor level) to the anal verge, which is defined as the outer open- ing of the gastrointestinal tract. The anal verge is at the level of the squamous- mucocutaneous junction with the perianal skin.5,6 The authors have nothing to disclose. -
HPV, Anal Dysplasia and Anal Cancer
HPV, anal dysplasia FACT and anal cancer SHEET Published 2016 Summary Anal cancer typically develops over a period of years, beginning with a precancerous condition called anal dysplasia. CONTACT US Anal dysplasia occurs when clusters of abnormal cells form by telephone lesions in the mucosa lining of the anal canal (between the 1-800-263-1638 anus and the rectum). The lesions typically form inside the anal 416-203-7122 canal or just outside the anal opening. by fax 416-203-8284 Although there are over 100 different types of the human papillomavirus (HPV), anal dysplasia is usually caused by certain by e-mail strains of HPV which can be transmitted sexually. HPV can shut [email protected] off the proteins that help prevent dysplasia and cancer cells from developing, therefore leading to HPV-associated diseases by mail such as anal dysplasia. 555 Richmond Street West Suite 505, Box 1104 It is difficult to screen for anal dysplasia since the lesions are Toronto ON M5V 3B1 not detectable by routine examinations. As a result, anal dysplasia is often not detected until it has developed into anal cancer, which can be difficult to treat depending on the severity. Specific screening tests can detect dysplasia or precancerous changes. If these precancers are treated, anal cancer may be prevented. Anal cancer is usually treated with radiation and chemotherapy or with surgery. Although anal dysplasia may be treated successfully, individuals with HIV are at increased risk of it recurring and may need to be monitored closely by a trained physician. Consistent condom use reduces, but does not eliminate, the risk of transmitting HPV. -
Tumor Budding Is Associated with an Increased Risk of Lymph Node
Modern Pathology (2014) 27, 1578–1589 1578 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 Tumor budding is associated with an increased risk of lymph node metastasis and poor prognosis in superficial esophageal adenocarcinoma Michael S Landau1, Steven M Hastings1, Tyler J Foxwell1, James D Luketich2, Katie S Nason2 and Jon M Davison1 1Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA and 2Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA The treatment approach for superficial (stage T1) esophageal adenocarcinoma critically depends on the pre-operative assessment of metastatic risk. Part of that assessment involves evaluation of the primary tumor for pathologic characteristics known to predict nodal metastasis: depth of invasion (intramucosal vs submucosal), angiolymphatic invasion, tumor grade, and tumor size. Tumor budding is a histologic pattern that is associated with poor prognosis in early-stage colorectal adenocarcinoma and a predictor of nodal metastasis in T1 colorectal adenocarcinoma. In a retrospective study, we used a semi-quantitative histologic scoring system to categorize 210 surgically resected, superficial (stage T1) esophageal adenocarcinomas according to the extent of tumor budding (none, focal, and extensive) and also evaluated other known risk factors for nodal metastasis, including depth of invasion, angiolymphatic invasion, tumor grade, and tumor size. We assessed the risk of nodal metastasis associated with tumor budding in univariate analyses and controlled for other risk factors in a multivariate logistic regression model. In all, 41% (24 out of 59) of tumors with extensive tumor budding (tumor budding in Z3 20X microscopic fields) were metastatic to regional lymph nodes, compared with 10% (12 out of 117) of tumors with no tumor budding, and 15% (5 out of 34) of tumors with focal tumor budding (Po0.001). -
Incidence of Recurrent High-Grade Anal Dysplasia in HIV-1-Infected Men and Women Following Infrared Coagulation Ablation: a Retrospective Cohort Study
pathogens Article Incidence of Recurrent High-Grade Anal Dysplasia in HIV-1-Infected Men and Women Following Infrared Coagulation Ablation: A Retrospective Cohort Study Javier Corral 1,2,3,*, David Parés 1,2,3, Francesc García-Cuyás 1,2, Boris Revollo 2,4, Ana Chamorro 2,4, Carla Lecumberri 2,5 , Antoni Tarrats 2,5, Eva Castella 6, Marta Piñol 1,2, Bonaventura Clotet 2,3,7, Sebastià Videla 2,8,*,† and Guillem Sirera 2,4,† 1 Department of General Surgery, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; [email protected] (D.P.); [email protected] (F.G.-C.); [email protected] (M.P.) 2 Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; brevollo@flsida.org (B.R.); achamorro@flsida.org (A.C.); [email protected] (C.L.); [email protected] (A.T.); [email protected] (B.C.); gsirera@flsida.org (G.S.) 3 School of Medicine, Universitat Autónoma de Barcelona (UAB), Edifici M, Av. de Can Domènech, Bellaterra, 08193 Barcelona, Spain 4 HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain 5 Department of Obstetrics and Gynaecology, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain 6 Department of Pathology, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, Citation: Corral, J.; Parés, D.; 08916 Barcelona, Spain; [email protected] García-Cuyás, F.; Revollo, B.; 7 Retrovirology Laboratory IrsiCaixa Foundation, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain Chamorro, A.; Lecumberri, C.; Tarrats, 8 Department of Clinical Pharmacology, Bellvitge University Hospital/IDIBELL/University of Barcelona, A.; Castella, E.; Piñol, M.; Clotet, B.; Hospitalet de Llobregat, Gran Via de les Corts Catalanes 199–203, 08907 Barcelona, Spain et al. -
Use of Human Papillomavirus Ge
Use of human papillomavirus genotyping and biomarkers for targeted screening of anal dysplasia in human immunodeficiency virus-infected patients Clarisse Dupin, Laurent Siproudhis, Sébastien Hénno, Sophie Minjolle, Cédric Arvieux, Pierre Tattevin To cite this version: Clarisse Dupin, Laurent Siproudhis, Sébastien Hénno, Sophie Minjolle, Cédric Arvieux, et al.. Use of human papillomavirus genotyping and biomarkers for targeted screening of anal dysplasia in human immunodeficiency virus-infected patients. Digestive and Liver Disease, WB Saunders, 2015, 47(5), pp.423-428. 10.1016/j.dld.2015.01.150. hal-01147275 HAL Id: hal-01147275 https://hal-univ-rennes1.archives-ouvertes.fr/hal-01147275 Submitted on 22 Oct 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Use of human papillomavirus genotyping and biomarkers for targeted screening of anal dysplasia in human immunodeficiency virus-infected patients Clarisse Dupin,a,b, Laurent Siproudhis,b,c Sébastien Henno,b,d Sophie Minjolle,a,b Cédric Arvieux,b,e Pierre Tattevinb,e Department of Virology, Pontchaillou